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Shiga toxin-producing Escherichia coli (STEC) is an important cause of gastroenteritis (GE) 23 
and haemolytic uremic syndrome (HUS). Incidence of STEC-illness is largely underestimated 24 
in notification data, particularly of serogroups other than O157 (“non-O157”). Using HUS 25 
national notification data (2008-2012, excluding 2011), we modelled true annual incidence of 26 
STEC-illness in Germany separately for O157 and non-O157 STEC, taking into account the 27 
groups’ different probabilities of causing bloody diarrhoea and HUS, and the resulting 28 
difference in their ascertainment. Uncertainty of input parameters was evaluated by stochastic 29 
Monte Carlo simulations. Median annual incidence of STEC-associated HUS and STEC-GE 30 
was estimated at 0.11 (95% CrI 0.08-0.20), and 34.6 (95% CrI 12-145) per 100,000 31 
population, respectively. German notification data underestimated STEC-associated HUS and 32 
STEC-GE incidences by factors of 1.8 and 32.3, respectively. Non-O157 STEC accounted for 33 
78% of all STEC-GE, 51% of all bloody STEC-GE and 32% of all STEC-associated HUS 34 
cases. Non-O157 serogroups dominate incidence of STEC-GE and contribute significantly to 35 
STEC-associated HUS in Germany. This might apply to many other countries considering 36 
European surveillance data on HUS. Non-O157 STEC should be considered in parallel to 37 
STEC O157 when searching aetiology in patients with GE or HUS, and accounted for in 38 
modern surveillance systems.39 
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Shiga toxin-producing Escherichia coli (STEC) is an important cause of gastroenteritis (GE) 41 
and life-threatening haemolytic uremic syndrome (HUS) in many countries. STEC has a 42 
zoonotic reservoir (mainly ruminants) and is transmitted by inadvertent ingestion of small 43 
amounts of faecal matter. The serotype is an indicator of the genomic strain content and 44 
incidence of human illness and disease severity varies by serotype [1, 2]. Evidence from 45 
observational studies suggest that STEC of serogroup O157 with serotypes H7 or H- (O157 46 
STEC) are, on average, substantially more virulent than other (“non-O157”) STEC implicated 47 
with human illness [2-4]. O157 STEC is the leading cause of paediatric HUS [5] and the most 48 
frequently isolated etiologic agent in STEC outbreaks worldwide [6]. These organisms can be 49 
easily identified by culture on selective and differential agar [7], except rarely identified 50 
sorbitol-fermenting (sf) clones [8, 9]. 51 
Non-O157 STEC represents a genomically heterogeneous group of organisms, comprising 52 
STEC with little or no virulence to humans but also, for example, STEC O104:H4 that caused 53 
the largest outbreak of HUS thus far [10]. Currently, diagnosis of non-O157 STEC is more 54 
complex and requires screening for Shiga toxins or their encoding genes. Culture isolation 55 
and subsequent serotyping is often conducted only at public health laboratories. Diagnosis of 56 
non-O157 STEC is disproportionately underutilized, even in countries where their diagnosis 57 
is recommended. Consequently, surveillance for non-O157 STEC in many countries is less 58 
inclusive than for O157 STEC and their contribution to incidence of STEC illness has been 59 
insufficiently determined. 60 
Notification data, including statutory, capture only a fraction of illnesses that is occurring in 61 
the population. In Germany, median annual incidence (per 100,000 population) of 62 
Kuehne A, et al: Estimating true incidence of O157 and non-O157 Shiga toxin-producing Escherichia coli illness in Germany 
based on notification data of haemolytic uraemic syndrome. Epidemiol Infect. 2016 Jul 29:1-11. [Epub ahead of print]  
4 
 
notifications reports 0.06 cases for STEC-associated HUS (and 1.07 cases for STEC-GE) for 63 
2008-2012 excluding 2011 (https://survstat.rki.de, data version 01/07/2014).  64 
Studies addressing underestimation in notification data and the quantitative relation of non-65 
O157 STEC to O157 STEC are helpful to inform diagnostic and surveillance strategies – as 66 
were previous studies for other gastroenteric pathogens [11]. 67 
The few available studies suggest a true annual incidence of STEC-associated infections 68 
between 47 and 100 per 100000 population for Europe [12] and Northern America [13, 14] 69 
and 0.15 STEC-associated HUS [12]. Estimated proportions of non-O157 in STEC-GE were 70 
62% and 64% in Canada [14] and the United States [13] respectively. All available studies 71 
extrapolated data from different countries or data on other pathogens than STEC for their 72 
estimation models [12-14], thus introducing a further source adding to the inherent 73 
uncertainty of stochastic modelling. Furthermore, estimates of overall STEC-GE and the 74 
proportion of O157 STEC are based, at best, on STEC-GE surveillance data [13] with all its 75 
diagnostic vagaries mentioned afore, or on assumptions [12, 14] but not on HUS statutory 76 
surveillance data. 77 
Our objectives were to estimate annual frequency and incidence of STEC-associated HUS and 78 
STEC-GE in Germany based on German national notification data for enteropathic HUS – 79 
overall and separately for O157 STEC and non-O157 STEC - to inform diagnostic-, and 80 
surveillance-strategies. 81 
Methods 82 
Using HUS national notification data as a starting point, we modelled true annual incidence of 83 
STEC-illness in Germany separately for O157 and non-O157 STEC, taking into account 84 
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group specific underestimation caused by underreporting of notification data and 85 
ascertainment, see Figure 1. 86 
Diagnosis and surveillance of STEC-GE and “enteropathic” HUS in Germany 87 
In Germany, diagnosis of STEC in GE and HUS patients is based on detection of Shiga toxins 88 
or their encoding genes in stool enrichment culture or isolates. Subsequent culture isolation 89 
and serotyping is recommended but not mandatory and rarely performed in clinical 90 
laboratories. In HUS patients, evidence for an STEC infection can also be established by 91 
detecting anti-lipopolysacharide IgM antibodies against E. coli serogroups in blood by 92 
specialised laboratories (which in the study period included only antibodies against the 93 
serogroup O157).  94 
According to the German Protection against Infection Act, both laboratory detection of STEC 95 
infection in stool and clinically diagnosed “enteropathic” (i.e. GE-associated) HUS are 96 
notifiable (see supplementary material for national surveillance case definitions).  97 
Electronic case reports are sent from the local health department via State Health Departments 98 
to the federal-level public health institute, the Robert Koch Institute (RKI), where reports are 99 
hosted in a national database. In addition, RKI conducts active surveillance for paediatric 100 
HUS since 2008 in collaboration with the German Society for Paediatric Nephrology. This 101 
surveillance entails monthly inquiries to all paediatric nephrology centres (PNC) in Germany 102 
about incident HUS cases in children (<18y) of the past month. 103 
Risk model for STEC illness in Germany  104 
We used German notification data on enteropathic HUS, reported to the RKI for the years 105 
2008-2012 (excl. 2011 because of a large outbreak of STEC O104:H4 [10]) as the basis to 106 
estimate the true annual incidence of STEC-GE in Germany.  107 
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We computed estimates separately for the groups of STEC O157 and non-O157 STEC, taking 108 
into account the groups’ different average capability of causing acute bloody diarrhoea [15], 109 
and HUS and the resulting difference in underascertainment caused by symptomatic cases not 110 
attending health facilities (for differences in clinical severity) or by not being correctly 111 
diagnosed as a case (for differences in diagnostics as outlined above). Furthermore, 112 
underreporting of cases from health facilities to public health authorities adds to 113 
underestimation of STEC-GE incidence.  114 
Our estimations were conducted in the following sequence (see also Figure 1): 115 
a) Adjustment for underreporting of HUS  116 
To estimate the true median annual number of enteropathic HUS, adjustment for 117 
underreporting was conducted separately for cases treated in PNCs and non-PNCs. For 118 
PNCs, we used a two-source capture-recapture approach (statutorily passive HUS 119 
surveillance and active paediatric HUS surveillance) to estimate the magnitude of 120 
underreporting of notification data. We assumed underreporting by non-PNCs to be up to 121 
ten times more common than in PNCs as HUS cases are infrequently treated in these 122 
institutions. Consequently, knowledge of infectious disease notification requirements, 123 
otherwise seldom needed in nephrology units, is likely to be less prevalent among medical 124 
personnel in non-PNCs.  125 
b) Estimating the proportion of STEC-associated HUS 126 
Evidence of STEC infection cannot be established in every case of “enteropathic” HUS. 127 
Using literature (described in detail in the supplementary material) on microbiological 128 
evidence of STEC in HUS patients in Germany, we estimated the proportion of 129 
enteropathic HUS caused by STEC infection [17]. This proportion was subsequently 130 
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multiplied by the estimated number of all HUS cases per year to obtain the number of 131 
estimated STEC-associated HUS cases. 132 
c) Estimating the proportion of O157 and non-O157 among STEC-associated HUS  133 
The proportion of O157 among STEC-associated HUS in Germany was derived from 134 
literature [17, 18] and combined in a beta distribution as outlined in Table 1. This 135 
proportion was multiplied by the annual number of STEC-associated HUS cases to 136 
estimate the O157-associated HUS cases (the remaining STEC-HUS cases were thus non-137 
O157 associated). All further calculations were conducted separately for O157 and non-138 
O157 -associated HUS cases.  139 
d) Estimating the number of laboratory confirmed STEC-GE cases per HUS case  140 
Using literature information on the proportion of HUS-cases among laboratory-confirmed 141 
STEC-GE cases [19], we multiplied the estimated annual number of STEC-associated 142 
HUS cases by the factor for STEC-GE cases per STEC-associated HUS case separately 143 
for O157 and non-O157 (beta distribution).  144 
e) Estimating the proportion of bloody diarrhoea among O157 and non O157 STEC-GE 145 
cases 146 
In addition, we used literature for estimates on the proportion of bloody diarrhoea among 147 
O157 and non-O157 STEC-GE cases [19]. Annual frequencies for STEC-GE with bloody 148 
and non-bloody diarrhoea were used to account for underascertainment according to 149 
severity in a next step (separately for O157 and non-157). 150 
f) Estimated underascertainment of bloody and non-bloody diarrhoea  151 
Underascertainment was accounted for in a procedure incorporating three steps: Using 152 
literature information, we first estimated the proportion of symptomatic patients consulting 153 
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a physician, thereafter the proportion of patients that provided stool specimens for 154 
microbiological testing [20, 21] and finally the proportion of stool samples tested for STEC 155 
[22] based on German laboratory recommendations on test strategies for faecal samples 156 
[22].  157 
The estimated annual number of true STEC-GE cases and STEC-associated HUS cases in 158 
Germany, differentiated for O157 and non-O157, were converted to annual cumulative 159 
incidence per 100000 population, using the mean population size of Germany 2008-2012, 160 
excluding 2011, obtained from Germany’s Federal Statistical Office. 161 
Evaluation of uncertainty 162 
We used Monte Carlo simulation in @RISK version 6.1.1 (Palisade Corporation, Ithaca, NY) 163 
with Latin Hypercube sampling and 10000 iterations to evaluate uncertainty in the outputs. 164 
All input data was considered to be subject to uncertainty and parameters were therefore 165 
described by probability distributions. Generally, proportions were described by beta 166 
distributions and the HUS rate was described by a gamma distribution [16]. Pert distributions 167 
were used for multiplication factors where sufficient data to inform beta-distributions was 168 
unavailable.  Distribution parameterization was done as displayed in Table 1. The results are 169 
reported as the median and the 95% credible interval.  170 
A sensitivity analysis was conducted to evaluate the contribution of the input parameters to 171 
the overall uncertainty in outcome estimates to identify which input parameter shows the 172 
biggest influence on the output.  173 
In addition we examined two scenarios using alternative values of particularly uncertain input 174 
parameters to investigate their effect on the outcome estimates (keeping all other variables of 175 
the model constant). For details see supplementary material. In a conservative Scenario (1) we 176 
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assumed that degree of underreporting of HUS did not differ between PNCs and non-PNCs 177 
and that all stool samples submitted for microbiological testing were investigated for STEC 178 
regardless of whether blood was visible. In Scenario 2 we re-parameterized the model using 179 
input parameters for underascertainment based on findings of a survey in the Federal State of 180 
Hesse for in children <16 years of age [21], to account in our estimates for 181 
underascertainment for the higher incidence of STEC illness in children.  182 
Literature survey 183 
We searched Medline and SCOPUS literature for information about STEC in Germany 184 
published since inception of Medline and SCOPUS bibliographic database to 31/12/2014 with 185 
the objective to identify for patients in Germany the proportion of STEC-associated HUS 186 
among enteropathic HUS cases (as input parameter for estimation step b), the proportion of 187 
O157 STEC among STEC-associated HUS (step c) and the proportion of HUS and bloody 188 
diarrhoea among laboratory confirmed STEC-GE separately for O157 and non-O157 189 
serogroups (step d). Our second objective was to identify underascertainment of bloody and 190 
non-bloody diarrhoea (step f), including the proportion of physician consultations in cases of 191 
bloody and non-bloody diarrhoea and the proportion of physicians taking stool samples in 192 
cases of bloody and non-bloody diarrhoea. 193 
We used the search terms (enterohemorrhagic escherichia coli OR stec OR escherichia coli 194 
o157 OR e coli o157) AND (Germany) to identify input parameters for step b-e. We used 195 
search terms (gastroenteritis OR gastrointestinal illness OR gastrointestinal infections) AND 196 
Germany AND (healthcare OR medical care) in titles and abstracts for step f.  197 
We required articles for all steps to provide data in sufficient detail for O157 and non-O157 198 
regarding proportion of HUS and bloody diarrhoea and to refer to data that pertained to 199 
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Germany recognizing that serogroup distribution among GE and HUS cases as well as health 200 
seeking behaviour may vary between countries. In addition, we required information for steps 201 
d-f to be derived from population-based surveys or sentinel surveillance projects to increase 202 
accuracy of these estimates. Search results for Medline and Scopus were combined and de-203 
duplicated. Two investigators screened documents independently, in case of discrepancies 204 
consensus in discussion was sought. Documents were first screened by reviewing titles and 205 
abstracts were available. Identified documents were screened against inclusion and exclusion 206 
criteria outlined above. From the identified documents absolute numbers were extracted and 207 
used as input variables in the estimation model as outlined in Table 1. 208 
Results 209 
We identified five relevant publications, three for step b to e and two for step f [17-21] that 210 
together provided information for all required input parameters, see Figure 2 and 211 
supplementary material. These publications, German notification data and German laboratory 212 
guidelines formed the backbone of the simulation model and are outlined in Table 1.  213 
We estimated a median annual number of 90 cases of STEC-associated HUS in Germany 214 
during the study period, corresponding to an incidence of 0.11 (95% CrI 0.08-0.20) per 215 
100000 population; a median of 60 cases due to STEC O157 (incidence 0.07; 95% CrI 0.05-216 
0.13) and a median of 29 cases due to non-O157 STEC (incidence 0.04; 95% CrI 0.03-0.07), 217 
see Table 2. From these, we estimated that a median of 28347 STEC-GE cases occurred per 218 
year in the German population, indicating an incidence of 34.6 (95% CrI 12.0-145) per 219 
100000 population; a median of 4969 cases due to O157 STEC (incidence 6.07; 95% CrI 2.2-220 
23.7) and a median of 22019 cases due to non-O157 STEC (incidence 26.9; 95% CrI 8.0-221 
133).  222 
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Our estimates correspond to a median annual underestimation of STEC-associated HUS and 223 
STEC-GE in the German notification data by a factor of 1.8 (1.3-3.3) and 32.3 (11.2-135) 224 
respectively. 225 
Non-O157 STEC accounted for 81% (49%-96%) of all STEC-GE and 51% (16% - 86%) of 226 
all bloody STEC-associated diarrhoea. 227 
Sensitivity analysis indicated that the proportion of HUS cases among laboratory confirmed 228 
non-O157 STEC exerted the biggest influence on the outcome of all input parameters, 229 
followed by the proportion of stool samples tested for STEC and the completeness of HUS-230 
notifications from non-PNCs, see Figure 3.  231 
In scenario analysis, the median annual incidence of STEC-GE ranged from 17.1 (95%-CI: 232 
7.6-61) per 100000 population in scenario 1 to 72 (95%-CI: 22.3-339) in scenario 2 and of 233 
STEC-associated HUS from 0.08 (95%-CI: 0.07-0.09) in scenario 1 to 0.11 (95% CrI 0.08-234 
0.20) in scenario 2 (unchanged to the point estimate). 235 
The proportion of non-O157 STEC among STEC-GE, bloody diarrhoea and STEC-associated 236 
HUS did not vary in the different scenarios (see supplementary material for detailed results).   237 
Discussion 238 
We estimated the true frequency and incidence of STEC illness in the German population, 239 
separately for O157 and non-O157 STEC, based on statutory notification data on HUS. The 240 
study yielded the following main findings: The median annual incidence per 100000 241 
population was estimated at 34.6 (95% CrI 12.00-145.00) for STEC-GE and 0.11 for STEC-242 
associated HUS (95% CrI 0.08-0.20). German notification data underestimated STEC-243 
associated HUS and STEC-GE incidences by factors of 1.8 and 32.3, respectively. Non-O157 244 
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STEC accounted for approximately 80% of all STEC-GE, half of all bloody STEC-associated 245 
diarrhoea and one-third of all STEC-associated HUS cases, hence contributing to STEC-246 
illness to an even larger extent than previously estimated [13, 14].  247 
Our incidence point estimates for STEC-GE and HUS are slightly lower than those published 248 
for Europe (47 and 0.15 respectively) [12], the United States (59 for STEC-GE) [13] and 249 
Canada (100 for STEC-GE) [14], but in keeping considering the degree of uncertainty 250 
accompanying our estimate. Particularly the incidence for O157-STEC-GE is lower than 251 
estimated for other European countries such as the Netherlands [20, 23], Denmark or the 252 
United Kingdom [20], and for the United States and Canada [12, 13]. In Germany, neither 253 
laboratory-based (passive) surveillance of STEC-GE nor (active) HUS-surveillance ever 254 
identified an outbreak with “classical” non-sorbitol fermenting O157-STEC comprising five 255 
persons or more, but did so for outbreaks with other serotypes [24, 25]. We are unaware of 256 
specific control plans for O157 STEC in animal reservoirs or the food-production chain that 257 
would explain this observation. Thus, our estimation of a comparatively low O157-STEC 258 
incidence adds additional weight to the view that O157-STEC pose a limited public health 259 
problem in Germany.  260 
Of note, according to surveillance data (2008-2012, excl. 2011) reported to the European 261 
Centre for Disease Control and Prevention (ECDC) from other countries in the European 262 
Union, a slightly higher percentage (40%, 391/659) of all STEC identified in reported HUS 263 
patients belonged to non-O157 serogroups (data provided by ECDC extracted from The 264 
European Surveillance System - TESSy). This may indicate that non-O157 STEC contribute 265 
to STEC-GE incidence in other European countries even more than in Germany (where non-266 
O157 STEC account for 80% of STEC-GE). Yet, only 33% of STEC-GE captured in 267 
surveillance systems in Europe were attributed to infection by non-O157 strains during the 268 
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study period [26, 27], underscoring the large degree of underascertainment of these STEC 269 
strains in GE patients in Europe. In recent years, the proportion of non-O157 STEC increased, 270 
likely indicating a more frequent use of serogroup-independent testing in Europe [26, 27]. 271 
In Germany, the contribution of the different non-O157 serogroups to STEC-illness remained 272 
fairly constant over the last 10 years (except in 2011) according to German surveillance data  273 
with serogroups O26, O103 being the most frequently isolated non-O157 STEC in children 274 
and O91 in adults [19, 28]. The numerous different non-O157 STEC vary dramatically in 275 
their virulence. On average though, they less frequently causes life-threatening HUS (in 276 
children) or disease outbreaks, and, importantly, their diagnosis currently is more complex, 277 
time-consuming and expensive. Thus, the question about the cost-effectiveness of screening 278 
for non-O157 has been raised [29, 30]. Apart from their markedly more frequent occurrence 279 
as etiologic agent in human GE than STEC O157 and their substantial contribution to the 280 
burden of bloody diarrhoea and HUS, new STEC strains are likely to evolve of which some 281 
will cause outbreaks (e.g., STEC O104:H4)[10]. For the latter reason alone we believe that 282 
modern STEC diagnosis and consequently surveillance systems should encompass timely 283 
detection of non-O157 STEC (including information on the serotype or other 284 
epidemiologically meaningful subtyping information), even in countries where STEC O157 285 
appears to dominate. 286 
Validity of risk model 287 
Our “top-down” approach of estimating STEC incidence based on HUS notification data is 288 
new and we believe is advantageous for at least two reasons. Firstly, statutory HUS 289 
surveillance is more sensitive than STEC-GE surveillance and in conjunction with active 290 
paediatric HUS surveillance in Germany allowed for an accurate estimate of its 291 
underreporting. Furthermore, STEC aetiology in (paediatric) HUS patients has been 292 
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extensively studied in Germany [17, 18]. Taken together, HUS incidence and the individual 293 
contribution of O157 and non-O157 STEC could be estimated with little uncertainty.  294 
Second, our estimations were purposively based solely on information on STEC in Germany, 295 
preventing the need of extrapolating from data gathered in other countries as another source 296 
of uncertainty.  297 
By far the greatest source of uncertainty was the proportion of HUS among patients infected 298 
by a non-O157 STEC because it was based on small numbers. However, our estimate is in 299 
agreement with data from other countries  [31]. Likewise, other findings are corroborated by 300 
data sources not used in our estimation. For example, the estimated proportion of non-O157 301 
STEC-associated HUS (33%) is consistent with that observed in national HUS notification 302 
data during the study period (34%). Furthermore, the proportion of non-O157 serogroups in 303 
STEC-GE and STEC-associated bloody diarrhoea in Germany is consistent with both national 304 
notification data on STEC-GE and with a nationwide laboratory sentinel conducted at the 305 
beginning of the century in Germany [19].  306 
Limitations 307 
As previously published risk models, ours did not account for the effect of age because age-308 
specific data was unavailable for many estimation steps. Yet, the serogroup-specific incidence 309 
for STEC-GE and the HUS-incidence vary with age. Most available studies focussed 310 
exclusively or primarily on children (who should have the highest true incidence of STEC-GE 311 
and HUS in Germany), which is why uncertainty of estimates is likely highest for adults.  312 
In addition, non-O157 STEC consist of different pathogens with a variety of virulence genes 313 
and estimates for non-O157 relate to the (fairly stable) distribution of different strains in 314 
Germany and can be different in other countries. However, virulence based model input data 315 
for different non-O157 strains were not available in sufficient detail. 316 
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Furthermore, some input data of our risk model lack an evidence base as no study was 317 
available to support our assumptions, such as underreporting from non-PNCs and the 318 
adherence to lab guidelines for testing stool samples of gastroenteritis cases. These two 319 
parameters were among the top-3 influential parameters in the sensitivity analysis, warranting 320 
further data collection to decrease this uncertainty. Furthermore, not all literature sources used 321 
for our risk model distinguished between (rare) sf-O157 STEC and (“classic”) non-sf O157 322 
STEC. Because sf-O157 STEC infection progresses with a higher probability from diarrhoea 323 
to HUS [32], we slightly overestimated STEC-GE incidence of serogroup O157.  324 
Completeness of HUS notification is likely overestimated in this study because concurrently 325 
conducted active paediatric surveillance included reminders of notification obligations when 326 
continuously monitoring HUS cases ascertained in the active system. 327 
Conclusions 328 
Statutory notification data largely underestimate STEC-GE in Germany, where STEC 329 
diagnosis is based on serogroup-independent testing for Shiga toxins or their encoding genes.  330 
Contribution of non-O157 serogroups to STEC GE incidence appear to be higher than 331 
previously estimated [13, 14], not only including a large number of mild illnesses but also 332 
half of all STEC-associated bloody diarrhoea cases. Considering European surveillance data 333 
on HUS, this finding is probably true for many other countries in Europe. Surveillance of 334 
HUS complements that of STEC-GE, not only by allowing for detecting outbreaks that 335 
otherwise go unrecognized [33] and reliably monitoring trends of STEC infection [34], but 336 
also by aiding in estimating STEC incidence estimating thereby helping to validate 337 
notification data. 338 
Non-O157 STEC should be considered in parallel to STEC O157 when searching aetiology in 339 
patients with GE or HUS, and accounted for in modern surveillance systems for STEC illness.  340 
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Table 1: Input parameters for the risk model to estimate true incidence of O157 and non-O157 STEC illness in 438 
Germany based on notification data of Haemolytic Uremic Syndrome (HUS) 439 
Steps in estimation Parameters S
#



























a. Adjustment for 
underreporting 
separately for cases 
treated in PNCs and 
non-PNCs 
Proportion of HUS-
notifications treated by 
PNCs 







notification from PNCs 






Multiplication factor to 
extrapolate completeness of 
notification from PNCs to 
non-PNCs 
- - Pert(0.1, 0.5, 1) 0.51 0.21 - 
0.84 
Assumption 






327 394 Beta(328, 68) 0.83 0.79 - 
0.86 
Gerber et al. 2002 
c. Proportion of O157 
and non-O157 among 
STEC-associated HUS 
Proportion of O157 in STEC-
associated HUS 
138 207 Beta(494, 239) 0.67 0.64 - 
0.71 
Gerber et al. 
2002;  
355 524 Mellmann et al. 
2008 
d. Number of 
laboratory confirmed 
STEC-GE cases per 
HUS case 
Proportion HUS among 
laboratory-confirmed STEC 
in O157 
3 27 Beta(4, 25) 0.13 0.04 - 
0.28 
Werber et al. 2007 
Proportion HUS among 
laboratory-confirmed STEC 
in non-O157 
2 149 Beta(3, 148) 0.02 0.00 - 
0.05 
Werber et al. 2007 
e. Proportion of 
bloody diarrhoea in 
O157 and non-O157 
among STEC-GE 
cases 
Proportion of cases 
experiencing bloody 
diarrhoea in O157 
10 27 Beta(11, 18) 0.38 0.22 - 
0.56 
Werber et al. 2007 
Proportion of cases 
experiencing bloody 
diarrhoea in non-O157 
16 149 Beta(17, 134) 0.11 0.07 - 
0.17 
Werber et al. 2007 
f. Underascertainment 
of bloody and non-
bloody diarrhoea 
Proportion of patients 
visiting physicians with 
bloody diarrhoea 
21 41 Beta(22,21) 0.51 0.36 - 
0.66 
Haagsma et al. 
2013 
Proportion of patients 
visiting physicians with non-
bloody diarrhoea 
458 1342 Beta(555, 1093) 0.34 0.31 - 
0.36 
Haagsma et al. 
2013;  
96 304 Hauri et al. 2011 
Proportion of physicians 
taking lab samples from 
patients with bloody 
diarrhoea 
10 20 Beta(11,11) 0.50 0.30 - 
0.70 
Haagsma et al. 
2013 
Proportion of physicians 
taking lab samples from 
patients with non-bloody 
diarrhoea 
155 456 Beta(170, 383) 0.31 0.27 - 
0.35 
Haagsma et al. 
2013;  
14 95 Hauri et al. 2011 
Proportion of stool samples 
tested for STEC from 
patients with bloody 
diarrhoea 
- - None 1.00 1.00 - 
1.00 
Kist et al. 2013 
Proportion of stool samples 
tested for STEC from 
patients with non-bloody 
diarrhoea 
- - Pert(0.1, 0.8, 1) 0.74 0.37 - 
0.96 








    
‡ The unit of measurement is person-years-at-risk for this parameter
      440 
*
 For Gamma(r, λ) r equals s and λ equals 1/N; For Beta(a, b), a equals Sum(s)+1 and b equals Sum(N)-Sum(s)+1 441 
Table 2: Results of modelling true median annual incidence and cases number of O157 and non-O157 STEC illness in Germany based on notification data of Haemolytic Uremic 
Syndrome (HUS) 

















(58 – 74) 
      
Incidence* 0.08 
(0.07 – 0.09) 






(80 – 197) 
      
Incidence* 0.13 
(0.10 – 0.24) 







(66 – 164) 
60 
(44 – 110) 
  29 
(21 – 54) 
  
Incidence* 0.11 
(0.08 – 0.20) 
0.07 
(0.05 – 0.13) 
  0.04 









(954 – 8864) 
486 
(199 – 1705) 
181 
(63 – 678) 
299 
(116 – 1079) 
1706 
(577 – 7999) 
189 
(58 – 908) 
1514 
(513 – 7096) 
Incidence* 2.83 




(0.08 – 0.83) 
0.37 
(0.14 – 1.32) 
2.09 
(0.70 – 9.80) 
0.23 
(0.07 – 1.11) 
1.85 







(10217 – 119041) 
4969 
(1835 – 19406) 
730 
(229 – 3037) 
4171 
(1449 – 16846) 
22019 
(6764 – 109046) 
769 
(211 – 3,925) 
21192 




(12.00 – 145.00) 
6.07 
(2.2 – 23,7) 
0.89 
(0.28 – 3.71) 
5.10 
(1.80 – 20.60) 
26.90 
(8.00 – 133.00) 
0.94 
(0.26 – 4.80) 
25,89 
(8.00 – 129.00) 
*per 100,000
Figures 
Figure 1: Modelling true annual incidence of O157 and non-O157 STEC illness in Germany based on 
notification data of Haemolytic Uremic Syndrome (HUS) 
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Figure 2: Results of the systematic review to identify input parameters for the estimation of the true incidence of 
O157 and non-O157 STEC illness in Germany based on notification data of Haemolytic Uremic Syndrome 
(HUS) 
Figure 3: Sensitivity analysis of influence of input parameters on frequency of STEC-GE in Germany based on notification data of Haemolytic Uremic Syndrome 
(HUS) 
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